skip to content

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

  •   Table of Contents

Download Guidelines

Appendix B: Drug Characteristics Tables

Characteristics of Fusion Inhibitor

Last Updated: January 29, 2008; Last Reviewed: April 8, 2015

Appendix B, Table 5. Characteristics of Fusion Inhibitor
Generic Name
Trade Name
Formulation Dosing Recommendation Serum Half-Life Elimination Storage Adverse Eventsa
  • Injectable; supplied as lyophilized powder
  • Each vial contains 108 mg of T20; reconstitute with 1.1 mL of sterile water for injection for delivery of approximately 90 mg/1 mL.
  • 90 mg (1 mL) sub-cutaneously BID
3.8 hours Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool
Store at room temperature (up to 25º C or 77º F). Re-constituted solution should be refrigerated at 2º to 8º C (36º to 46º F) and used within 24 hours.
  • Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in almost 100% of patients
  • Increased incidence of bacterial pneumonia
  • HSR (<1% of patients): Symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum trans-aminases. Re-challenge is not recommended.
a Also see Table 14.

Key to Abbreviations: BID = twice daily; HSR = hypersensitivity reaction; T20 = enfuvirtide

Download Guidelines